<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990961</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-0076</org_study_id>
    <nct_id>NCT03990961</nct_id>
  </id_info>
  <brief_title>Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)</brief_title>
  <official_title>Phase II Study of Pembrolizumab for PD-L1 Gene-Altered, Relapsed/Refractory DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A non randomized, unblinded, open label phase 2 study to investigate the efficacy of&#xD;
      pembrolizumab in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) with&#xD;
      PD-L1 genetic alterations&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Anticipated">August 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) to pembrolizumab treatment compared to historical controls.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) to pembrolizumab treatment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).</description>
    <arm_group_label>Pembrolizumab Treatment</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male/female participants who are at least 18 years of age on the day of signing&#xD;
             informed consent with a histologically confirmed diagnosis of DLBCL will be enrolled&#xD;
             in this study.&#xD;
&#xD;
             Note: Patients with high-grade B cell lymphomas not otherwised specified and those&#xD;
             with MYC and BCL2 translocations (double hit lymphoma) are eligible, as are patients&#xD;
             with transformed indolent lymphoma, so long as PD-L1 gene alterations are present.&#xD;
&#xD;
          2. A male participant must agree to use a contraception during the treatment period and&#xD;
             for at least 120 days after the last dose of study treatment. Participants must&#xD;
             refrain from donating sperm during this period.&#xD;
&#xD;
          3. A female participant is eligible to participate if she is not pregnant, not&#xD;
             breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               1. Not a woman of childbearing potential (WOCBP)&#xD;
&#xD;
               2. A WOCBP who agrees to follow the contraceptive guidance during the treatment&#xD;
                  period and for at least 120 days after the last dose of study treatment.&#xD;
&#xD;
             C.) patient must have negative pregnancy test within 72 hours of beginning treatment&#xD;
             if WOCBP&#xD;
&#xD;
          4. The participant (or legally acceptable representative if applicable) provides written&#xD;
             informed consent for the trial.&#xD;
&#xD;
          5. Have measurable disease, defined as at least one lesion that can be accurately&#xD;
             measured in at least two dimensions by CT scan. Minimum measurement must be &gt;15 mm in&#xD;
             the longest diameter by &gt;10 mm in the short axis. Lesions situated in a previously&#xD;
             irradiated area are considered measurable if radiographic progression has been&#xD;
             demonstrated in such lesions.&#xD;
&#xD;
          6. Participants must have available archived biopsy material (ideally to be performed&#xD;
             shortly before enrollment at the time of most recent relapse) for PD-L1 FISH and&#xD;
             correlative studies.&#xD;
&#xD;
          7. There is evidence of a PD-L1 gene alteration within lymphoma cells as assessed by&#xD;
             FISH.&#xD;
&#xD;
          8. Participants must have received ≥ 2 lines of prior systemic therapy, ≥ 1 line of prior&#xD;
             systemic therapy (if ineligible for or refused autologous stem cell transplantation),&#xD;
             or have received 1 line of prior therapy with primary-refractory disease or have&#xD;
             relapsed within 12 months from the time of initial diagnosis.&#xD;
&#xD;
             Note: patients having undergone prior CAR T cell therapy are eligible, as are patients&#xD;
             having received a prior allogeneic transplantation, provided they do not meet any of&#xD;
             the exclusionary GVHD criteria, and are at least 5 years removed from the date of&#xD;
             their transplant.&#xD;
&#xD;
          9. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
         10. Have adequate organ function within 10 days prior to the date of treatment allocation.&#xD;
             Please see below for Adequate Organ Function Laboratory Values:&#xD;
&#xD;
               -  Hematological&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) less than or equal to 1,000/microliters&#xD;
&#xD;
                    -  Platelets less than or equal to 50,000/microliters&#xD;
&#xD;
                    -  Hemoglobin less than or equal to 8.0 grams per decilitre&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
                    -  Creatinine OR measured or calculated clearance (GFR can also be used in&#xD;
                       place of creatinine or CrCl) greater than or equal to 1.5XULN OR less than&#xD;
                       or equal to 30mL/min for participant with creatinine levels less than 1.5 X&#xD;
                       institutional ULN&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
                    -  Total bilirubin greater than or equal to 1.5 X ULN or direct bilirubin&#xD;
                       greater than or equal to ULN for participants with total bilirubin levels&#xD;
                       less than 1.5 x ULN&#xD;
&#xD;
                    -  AST (SGOT) and ALT (SGPT) greater than or equal to 2.5 x ULN (greater than&#xD;
                       or equal to 5 x ULN for participants with liver metastases)&#xD;
&#xD;
               -  Coagulation&#xD;
&#xD;
                    -  International normalized ratio (INR) OR prothrombin time (PT) and Activated&#xD;
                       partial thromboplastin time (aPTT) greater than or equal to 1.5 x ULN unless&#xD;
                       participant is receiving anticoagulant therapy as long as PT or aPTT is&#xD;
                       within therapeutic range of intended use of anticoagulants.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment&#xD;
             allocation . If the urine test is positive or cannot be confirmed as negative, a serum&#xD;
             pregnancy test will be required.&#xD;
&#xD;
          2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with&#xD;
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4,&#xD;
             OX-40, CD137).&#xD;
&#xD;
          3. Has received chemotherapy, monoclonal antibody therapy, or targeted small molecule&#xD;
             therapy within 4 weeks prior to the first dose of study medication. Subjects must have&#xD;
             recovered (≤ Grade 1) from adverse events related to a previously administered agent&#xD;
             (patients with ≤ Grade 2 neuropathy are eligible). Subjects who have previously&#xD;
             received CAR T cell therapy are eligible provided that relapse occurred &gt; 90 days&#xD;
             following the date of CAR T cell infusion.&#xD;
&#xD;
             Note: If a participant received major surgery, he or she must have recovered&#xD;
             adequately from complications from the intervention prior to starting study treatment.&#xD;
&#xD;
          4. Has received prior radiotherapy within 1 week of start of study treatment.&#xD;
             Participants must have recovered from all radiation-related toxicities, not require&#xD;
             corticosteroids, and not have had radiation pneumonitis.&#xD;
&#xD;
          5. Has a histologic diagnosis of primary mediastinal lymphoma or gray zone lymphoma.&#xD;
&#xD;
          6. Has known active CNS lymphoma and/or lymphomatous meningitis. Participants with&#xD;
             previously treated brain metastases may participate provided they are radiologically&#xD;
             stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging&#xD;
             (note that the repeat imaging should be performed during study screening), clinically&#xD;
             stable and without requirement of steroid treatment for at least 14 days prior to&#xD;
             first dose of study treatment.&#xD;
&#xD;
          7. Has received a live vaccine within 30 days prior to the first dose of study drug.&#xD;
             Examples of live vaccines include, but are not limited to, the following: measles,&#xD;
             mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus&#xD;
             Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection&#xD;
             are generally killed virus vaccines and are allowed; however, intranasal influenza&#xD;
             vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.&#xD;
&#xD;
          8. Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to the first dose of&#xD;
             study treatment.&#xD;
&#xD;
          9. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days prior to the first dose of study drug. Short&#xD;
             courses of corticosteroids will be allowed for palliation of symptoms related to&#xD;
             lymphoma, but must be discontinued within 7 days prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
         10. Subjects having received prior allogeneic stem cell transplant, must be at least 5&#xD;
             years removed from the date of their transplant. The also must have no history of&#xD;
             severe (grade 3-4) acute GVHD, and/or current &gt; grade 1 acute GHVD. Subjects must not&#xD;
             have active chronic GVHD that requires active immune suppression or more than 10 mg of&#xD;
             prednisone/day or equivalent.&#xD;
&#xD;
         11. Has a history of a solid organ transplant.&#xD;
&#xD;
         12. Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 3 years.&#xD;
&#xD;
             Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of&#xD;
             the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that&#xD;
             have undergone potentially curative therapy are not excluded&#xD;
&#xD;
         13. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.&#xD;
&#xD;
         14. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
         15. Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
         16. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         17. Has a known history of Human Immunodeficiency Virus (HIV) infection.&#xD;
&#xD;
         18. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]&#xD;
             reactive) or known active Hepatitis C virus (defined as detection of HCV RNA)&#xD;
             infection.&#xD;
&#xD;
         19. Has a known history of active TB (Bacillus Tuberculosis).&#xD;
&#xD;
         20. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the study, interfere with the subject's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         21. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         22. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the study, starting with the screening visit through 120 days&#xD;
             after the last dose of trial treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin Kline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justin Kline, MD</last_name>
    <phone>773-702-5550</phone>
    <email>jkline@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Kline, MD</last_name>
      <phone>773-702-5550</phone>
      <email>jkline@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Justine Kline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

